Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors

Pharmacology Biochemistry and Behavior

Volumn 124, Issue , 2014, Pages 245-249

  Yoshimi, Noriko ^a,b   Fujita, Yuko ^a   Ohgi, Yuta ^a,b   Futamura, Takashi ^b   Kikuchi, Tetsuro ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Brexpiprazole; Cognition; Phencyclidine; Schizophrenia

Indexed keywords

BREXPIPRAZOLE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PHENCYCLIDINE; SEROTONIN 1A RECEPTOR; 7-(4-(4-(1-BENZOTHIOPHEN-4-YL)PIPERAZIN-1-YL)BUTOXY)QUINOLIN-2(1H)-ONE; DOPAMINE RECEPTOR; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXPLORATORY BEHAVIOR; MALE; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PRIORITY JOURNAL; ANIMAL; CHEMICALLY INDUCED; COGNITION DISORDERS; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE;

ANIMALS; COGNITION DISORDERS; MALE; MICE; MICE, INBRED ICR; PHENCYCLIDINE; QUINOLONES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE; THIOPHENES;

EID: 84903988963     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2014.06.008     Document Type: Article

References (52)

1. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15 2001 37 46 (Pubitemid 32242102)
2. 1A receptor in schizophrenia and during clozapine treatment J Psychopharmacol 18 2004 346 354 (Pubitemid 39386285)
3. 1A receptor in relation to human cognition Behav Brain Res 195 2008 103 111
4. C. Bourne, O. Aydemir, V. Balanza-Martinez, E. Bora, S. Brissos, and J.T. Cavanagh et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis Acta Psychiatr Scand 128 2013 149 162
5. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia Neuropsychopharmacology 15 1996 442 455 (Pubitemid 26389868)
6. J.T. Coyle, and G. Tsai The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia Psychopharmacology (Berl) 174 2004 32 38 (Pubitemid 38925088)
7. A.C. Dean, S.M. Groman, A.M. Morales, and E.D. London An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans Neuropsychopharmacology 38 2013 259 274
8. 11C]WAY-100,635 Psychopharmacology (Berl) 189 2006 155 164 (Pubitemid 44691538)
9. R. Freedman Schizophrenia N Engl J Med 349 2003 1738 1749 (Pubitemid 37315012)
10. Y. Fujita, T. Ishima, S. Kunitachi, H. Hagiwara, L. Zhang, and M. Iyo et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline Prog Neuropsychopharmacol Biol Psychiatry 32 2008 336 339 (Pubitemid 351178944)
11. M.F. Green, K.H. Nuechterlein, J.M. Gold, D.M. Barch, J. Cohen, and S. Essock et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria Biol Psychiatry 56 2004 301 307 (Pubitemid 39164514)
12. E.V. Gurevich, and J.N. Joyce Alterations in the cortical serotonergic system in schizophrenia: a postmortem study Biol Psychiatry 42 1997 529 545 (Pubitemid 27425471)
13. 1A receptor Eur Neuropsychopharmacol 18 2008 448 454
14. P.D. Harvey, A.P. Wingo, K.E. Burdick, and R.J. Baldessarini Cognition and disability in bipolar disorder: lessons from schizophrenia research Bipolar Disord 12 2010 364 375
15. K. Hashimoto, N. Okamura, E. Shimizu, and M. Iyo Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs Curr Med Chem 4 2004 147 154 (Pubitemid 38639374)
16. K. Hashimoto, Y. Fujita, E. Shimizu, and M. Iyo Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol Eur J Pharmacol 519 2005 114 117 (Pubitemid 43181173)
17. K. Hashimoto, E. Shimizu, and M. Iyo Dysfunction of glia-neuron communication in pathophysiology of schizophrenia Curr Psychiatry Rev 1 2005 151 163
18. K. Hashimoto, Y. Fujita, T. Ishima, H. Hagiwara, and M. Iyo Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: role of α7 nicotinic receptors Eur J Pharmacol 553 2006 191 195 (Pubitemid 44779614)
19. K. Hashimoto, Y. Fujita, and M. Iyo Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors Neuropsychopharmacology 32 2007 514 521
20. K. Hashimoto, Y. Fujita, T. Ishima, S. Chaki, and M. Iyo Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of glycine transporter-1 inhibitor NFPS Eur Neuropsychopharmacol 18 2008 414 421 (Pubitemid 351608551)
21. K. Hashimoto, T. Ishima, Y. Fujita, M. Matsuo, T. Kobashi, and M. Takahagi et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711 Biol Psychiatry 63 2008 92 97 (Pubitemid 350234890)
22. K. Hashimoto, B. Malchow, P. Falkai, and A. Schmitt Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders Eur Arch Psychiatry Clin Neurosci 263 2013 367 377
23. B.J. Hasselbalch, U. Knorr, and L.V. Kessing Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review J Affect Disord 134 2011 20 31
24. U. Heresco-Levy, and D.C. Javitt The role of N-methyl-d-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes Eur Neuropsychopharmacol 8 1998 141 152 (Pubitemid 28210341)
25. I. Hindmarch, and K. Hashimoto Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered Hum Psychopharmacol 25 2010 193 200
26. D.C. Javitt, and S.R. Zukin Recent advances in the phencyclidine model of schizophrenia Am J Psychiatry 148 1991 1301 1308
27. D.C. Javitt, S.R. Zukin, U. Heresco-Levy, and D. Umbricht Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia Schizophr Bull 38 2012 958 966
28. J.D. Jentsch, and R.H. Roth The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 1999 201 225 (Pubitemid 29067401)
29. 1A receptor Eur J Pharmacol 441 2002 137 140 (Pubitemid 34626163)
30. J.N. Joyce, A. Shane, N. Lexow, A. Winokur, M.F. Casanova, and J.E. Kleinman Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenia Neuropsychopharmacology 8 1993 315 336 (Pubitemid 23162958)
31. J.H. Krystal, D.C. D'Souza, I.L. Petrakis, A. Belger, R.M. Berman, and D.S. Charney et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders Harv Rev Psychiatry 7 1999 125 143 (Pubitemid 30240826)
32. S. Kunitachi, Y. Fujita, T. Ishima, M. Kohno, M. Horio, and Y. Tanibuchi et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of donepezil: role of sigma-1 receptors Brain Res 1279 2009 189 196
33. 2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia Biol Psychiatry 55 2004 225 233 (Pubitemid 38117158)
34. K. Maeda, H. Sugino, H. Akazawa, N. Amada, J. Shimada, and T. Futamura et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator J Pharmacol Exp Ther 2014 (in press)
35. H.Y. Meltzer The role of serotonin in antipsychotic drug action Neuropsychopharmacology 21 2 Suppl 1999 106S 115S (Pubitemid 29396478)
36. 1A receptors improve cognition in schizophrenia? Behav Brain Res 195 2008 98 102
37. 1A receptor agonism in antipsychotic drug action: rationale and perspective Curr Opin Investig Drugs 11 2010 802 812
38. 3H]WAY-100,635 binding affinity ratios: relationship to efficacy for G-protein activation Eur J Pharmacol 428 2001 177 184 (Pubitemid 33000139)
39. T. Niitsu, M. Iyo, and K. Hashimoto Sigma-1 receptor agonists as therapeutic drugs for cognitive impairments in neuropsychiatric disease Curr Pharm Des 18 2012 875 883
40. 1A receptors in learning and memory Behav Brain Res 195 2008 54 77
41. R.J. Porter, P. Gallagher, J.M. Thompson, and A.H. Young Neurocognitive impairment in drug-free patients with major depressive disorder Br J Psychiatry 182 2003 214 220 (Pubitemid 36286734)
42. L. Rajagopal, B.W. Massey, M. Huang, Y. Oyamada, and H.Y. Meltzer The novel object recogniton test in rodents in relation to cognitive impairment in schizophrenia Curr Pharm Des 2014 (in press)
43. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex Biol Psychiatry 48 2000 229 237 (Pubitemid 30618995)
44. 1A receptor activation Neuropsychopharmacology 21 1999 622 631 (Pubitemid 29486630)
45. T. Sumiyoshi, M. Matsui, S. Nohara, I. Yamashita, M. Kurachi, and C. Sumiyoshi et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment Am J Psychiatry 158 2001 1722 1725 (Pubitemid 32923670)
46. T. Sumiyoshi, M. Matsui, I. Yamashita, S. Nohara, M. Kurachi, and T. Uehara et al. The effect of tandospirone, a serotonin-1A agonist, on memory function in schizophrenia Biol Psychiatry 49 2001 861 868 (Pubitemid 32436390)
47. T. Sumiyoshi, S. Park, K. Jayathilake, A. Roy, A. Ertugrul, and H.Y. Meltzer Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study Schizophr Res 95 2007 158 168 (Pubitemid 47313647)
48. T. Sumiyoshi, Y. Higuchi, and T. Uehara Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia Front Behav Neurosci 7 2013 140
49. Y. Tanibuchi, Y. Fujita, M. Kohno, T. Ishima, Y. Takatsu, and M. Iyo et al. Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of adrenergic α1 receptors Eur Neuropsychopharmacol 19 2009 861 867
50. 11C]WAY-100,635 Arch Gen Psychiatry 59 2002 514 520 (Pubitemid 34602933)
51. T. Yoshida, M. Ishikawa, T. Niitsu, M. Nakazato, H. Watanabe, and T. Shiraishi et al. Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder PLoS One 7 2012 e42676
52. T. Yoshida, M. Iyo, and K. Hashimoto Recent advances in the potential therapeutic drugs for cognitive deficits in schizophrenia Curr Psychiatry Rev 8 2012 140 150